Pay in 4 interest-free payments of $49.50 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
Phase I clinical trial studies showed that in humans
IP administration of I-BET151 at 30 mg/kg once per day was shown to provide survival benefit in two distinct mouse models of murine MLL–AF9 and human MLL–AF4 leukaemia
RAS interacts with multiple targets in the cell and controls at least two signaling pathways
Ischemin was used at 10-50 µM final concentration in various in vitro assays
Molecular Weight: 560
N3-tri-EG-OSu - CAS# 1245718-89-1 Catalog No.:L60004 Phase I clinical trial studiesN3 tri EG OSu, CAS No. 1245718 89 1, is a PEG derivative containing an azide group and an NHS ester. The hydrophilic PEG spacer increases solubility in aqueous media. The azide group can react with alkyne, BCN, DBCO via Click Chemistry to yield a stable triazole linkage. The NHS ester can be used to label the primary amines ( NH2) of proteins, amine modified oligonucleotides, and other amine containing molecules. Product information CAS Number:
US$ 29.65
US$ 59.00
US$ 21.18
US$ 34.99
US$ 34.99